PRESS RELEASE: AiCuris Topical Pritelivir, a Highly Active Inhibitor for the Treatment of Herpes Simplex

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Genocea Biosciences, Inc. On September 26th, I wrote about Rational Vaccines (RVx), an Illinois-based company, which was formed in 2015 to develop vaccines that would prevent and treat herpes. http: //moderndesigninteriors. For more information, please visit the company’s website at www.genocea.com. Using ATLAS, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including Genocea’s ability to progress any product candidates in preclinical or clinical trials; the scope, rate and progress of its preclinical studies and clinical trials and other research and development activities; anticipated clinical trial results; that current results may not be predictive of future results; even if the data from preclinical studies or clinical trials is positive, regulatory authorities may require additional studies for approval and the product may not prove to be safe and efficacious; Genocea’s ability to enter into future collaborations with industry partners and the government and the terms, timing and success of any such collaboration; risks associated with the manufacture and supply of clinical and commercial product; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; Genocea’s ability to obtain rights to technology; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; the rate of cash utilized by Genocea in its business and the period for which existing cash will be able to fund such operation; Genocea’s ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity or debt financing or otherwise; general business conditions; competition; business abilities and judgment of personnel; the availability of qualified personnel and other factors set forth under “Risk Factors” in Genocea’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and other filings with the Securities and Exchange Commission (the “SEC”). Further information on the factors and risks that could affect Genocea’s business, financial conditions and results of operations is contained in Genocea’s filings with the SEC, which are available at www.sec.gov.


Genocea’s pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus, and earlier-stage programs in chlamydia, genital herpes prophylaxis, malaria and cancer immunotherapy. – Trial achieves primary endpoint – – Dose confirmed for subsequent trials –   – Phase 3 expected to start in 2H 2017 – – Company to host conference call at 9 a.m. Current genital herpes therapies only partially control clinical symptoms and viral shedding, a process which drives disease transmission. A replay of the R&D day can be accessed at: http://ir.genocea.com/events.cfm. In a study published Feb. This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. In addition, in 2011, the Company began to focus specifically on the development of life-saving cures for the treatment of Gram-negative infections to ensure effective resistance-breaking antibacterial therapeutic options for the future.

Using ATLAS, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. The goal of the collaboration is to identify the specificity and characteristics of T cells associated with protective T cell responses to potentially optimize clinical development and ultimately, clinical practice with CMP-001. I wrote this article myself, and it expresses my own opinions. This program leverages Genocea’s deep vaccinology experience along with ATLAS’s differentiated ability to select vaccine antigens based on an individual’s comprehensive T cell responses to the mutations in their own cancer. It’s news and information surrounding the phase 3 trial that we will now look to in order to form a medium-term bias. Potential applications of the company’s DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. Enrollment is ongoing in Vical’s first-in-human Phase 1 trial of its novel antifungal, VL-2397.

Guest speaker Charles G. Even higher infection rates are evident in developing countries, with further complications in people also infected with HIV. During that same period, those subjects reported a 48% reduction in genital lesion rates compared to baseline (p < 0.001). Positive feedback would allow the company to commence the phase III program on the candidate in the fourth quarter of 2017. Additionally the median density of colonization measured by microbiological culture for GEN-004 treated subjects ranged from zero to 2 colony forming units ("CFUs") per mL of nasal wash compared to one to 11 CFUs per mL for the placebo group.

Leave a Reply